Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 12, 2022
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 17, 2020
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
TPO-Mimetic Use in Children for Hematopoietic Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : Semaxanib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 19, 2019
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of AMG531(Romiplostim) in Patients With Aplastic Anemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 21, 2019
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 03, 2019
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2017
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 17, 2017
Lead Product(s) : Semaxanib
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable